{"id":"https://openalex.org/W2332684061","doi":"https://doi.org/10.1158/1538-7445.am2011-726","title":"Abstract 726: Erlotinib overcomes acquired resistance to cetuximab","display_name":"Abstract 726: Erlotinib overcomes acquired resistance to cetuximab","publication_year":2011,"publication_date":"2011-04-01","ids":{"openalex":"https://openalex.org/W2332684061","doi":"https://doi.org/10.1158/1538-7445.am2011-726","mag":"2332684061"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2011-726","doi":"https://doi.org/10.1158/1538-7445.am2011-726","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2011-726","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5003271971","display_name":"Toni Michel Brand","orcid":"https://orcid.org/0000-0002-6771-1283","observed_orcids":["https://orcid.org/0000-0002-6771-1283"]},"institutions":[{"id":"https://openalex.org/I135310074","display_name":"University of Wisconsin\u2013Madison","ror":"https://ror.org/01y2jtd41","country_code":"US","type":"education","lineage":["https://openalex.org/I135310074"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Toni M. Brand","raw_affiliation_strings":["1University of Wisconsin Madison, Madison, WI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of Wisconsin Madison, Madison, WI","institution_ids":["https://openalex.org/I135310074"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023671134","display_name":"Emily Dunn","orcid":"https://orcid.org/0009-0003-2246-3778","observed_orcids":["https://orcid.org/0009-0003-2246-3778"]},"institutions":[{"id":"https://openalex.org/I135310074","display_name":"University of Wisconsin\u2013Madison","ror":"https://ror.org/01y2jtd41","country_code":"US","type":"education","lineage":["https://openalex.org/I135310074"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Emily F. Dunn","raw_affiliation_strings":["1University of Wisconsin Madison, Madison, WI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of Wisconsin Madison, Madison, WI","institution_ids":["https://openalex.org/I135310074"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089257042","display_name":"Mari Iida","orcid":"https://orcid.org/0000-0001-7168-8680","observed_orcids":["https://orcid.org/0000-0001-7168-8680"]},"institutions":[{"id":"https://openalex.org/I135310074","display_name":"University of Wisconsin\u2013Madison","ror":"https://ror.org/01y2jtd41","country_code":"US","type":"education","lineage":["https://openalex.org/I135310074"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mari Iida","raw_affiliation_strings":["1University of Wisconsin Madison, Madison, WI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of Wisconsin Madison, Madison, WI","institution_ids":["https://openalex.org/I135310074"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Rebecca Myers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I135310074","display_name":"University of Wisconsin\u2013Madison","ror":"https://ror.org/01y2jtd41","country_code":"US","type":"education","lineage":["https://openalex.org/I135310074"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rebecca Myers","raw_affiliation_strings":["1University of Wisconsin Madison, Madison, WI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of Wisconsin Madison, Madison, WI","institution_ids":["https://openalex.org/I135310074"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101479660","display_name":"Chunrong Li","orcid":"https://orcid.org/0000-0002-3015-8461","observed_orcids":["https://orcid.org/0000-0002-3015-8461"]},"institutions":[{"id":"https://openalex.org/I135310074","display_name":"University of Wisconsin\u2013Madison","ror":"https://ror.org/01y2jtd41","country_code":"US","type":"education","lineage":["https://openalex.org/I135310074"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chunrong Li","raw_affiliation_strings":["1University of Wisconsin Madison, Madison, WI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of Wisconsin Madison, Madison, WI","institution_ids":["https://openalex.org/I135310074"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5039868720","display_name":"Deric L. Wheeler","orcid":"https://orcid.org/0000-0001-5915-3675","observed_orcids":["https://orcid.org/0000-0001-5915-3675"]},"institutions":[{"id":"https://openalex.org/I135310074","display_name":"University of Wisconsin\u2013Madison","ror":"https://ror.org/01y2jtd41","country_code":"US","type":"education","lineage":["https://openalex.org/I135310074"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Deric L. Wheeler","raw_affiliation_strings":["1University of Wisconsin Madison, Madison, WI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of Wisconsin Madison, Madison, WI","institution_ids":["https://openalex.org/I135310074"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I135310074"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"71","issue":"8_Supplement","first_page":"726","last_page":"726"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.6654999852180481,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.6654999852180481,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.3319999873638153,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9810000061988831},{"id":"https://openalex.org/keywords/cetuximab-resistance","display_name":"cetuximab resistance","score":0.9290000200271606},{"id":"https://openalex.org/keywords/acquired-drug-resistance","display_name":"acquired drug resistance","score":0.777999997138977},{"id":"https://openalex.org/keywords/egfr-inhibitors","display_name":"EGFR inhibitors","score":0.8009999990463257},{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.49900001287460327},{"id":"https://openalex.org/keywords/her2","display_name":"HER2","score":0.6520000100135803},{"id":"https://openalex.org/keywords/her3","display_name":"HER3","score":0.9890000224113464},{"id":"https://openalex.org/keywords/mapk-signaling","display_name":"MAPK signaling","score":0.8209999799728394},{"id":"https://openalex.org/keywords/akt-signaling","display_name":"Akt signaling","score":0.9850000143051147},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8579999804496765},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.7360000014305115},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7570000290870667},{"id":"https://openalex.org/keywords/tumor-xenografts","display_name":"tumor xenografts","score":0.5460000038146973},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.7120000123977661},{"id":"https://openalex.org/keywords/receptor-tyrosine-kinases","display_name":"receptor tyrosine kinase","score":0.6439999938011169}],"concepts":[{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.9700456857681274},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.9574035406112671},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.8277869820594788},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.6590557098388672},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6339128017425537},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.631475567817688},{"id":"https://openalex.org/C2909325608","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib Hydrochloride","level":5,"score":0.5237904787063599},{"id":"https://openalex.org/C75217442","wikidata":"https://www.wikidata.org/wiki/Q423650","display_name":"Protein kinase B","level":3,"score":0.5085750818252563},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4974968731403351},{"id":"https://openalex.org/C2780586478","wikidata":"https://www.wikidata.org/wiki/Q4688818","display_name":"Afatinib","level":5,"score":0.4962978959083557},{"id":"https://openalex.org/C2777329042","wikidata":"https://www.wikidata.org/wiki/Q420323","display_name":"Lapatinib","level":5,"score":0.47277453541755676},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.46992743015289307},{"id":"https://openalex.org/C2778332735","wikidata":"https://www.wikidata.org/wiki/Q417775","display_name":"Panitumumab","level":5,"score":0.44737234711647034},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.39885202050209045},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.27731892466545105},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.2761327922344208},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.27385252714157104},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.26782968640327454},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.2354678511619568},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.18560373783111572},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.12865734100341797},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.06920644640922546},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2011-726","doi":"https://doi.org/10.1158/1538-7445.am2011-726","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2011-726","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1965543774","https://openalex.org/W2004439203","https://openalex.org/W2265421862","https://openalex.org/W2093036951","https://openalex.org/W2327419907","https://openalex.org/W1969472096","https://openalex.org/W1494092082","https://openalex.org/W2039595652","https://openalex.org/W2042327295","https://openalex.org/W2999694147"],"abstract_inverted_index":{"Abstract":[0],"The":[1,95,369],"epidermal":[2],"growth":[3,326],"factor":[4],"receptor":[5,11],"(EGFR)":[6],"is":[7,16],"a":[8,19,127,145,302,322,342],"ubiquitously":[9],"expressed":[10],"tyrosine":[12,49],"kinase":[13,50],"(RTK)":[14],"and":[15,24,45,63,84,100,112,159,180,182,188,237,240,351,391,394],"recognized":[17],"as":[18,161,201,257,328,347,356],"key":[20],"mediator":[21],"of":[22,36,67,86,98,110,120,129,152,171,178,304,336,354,417,434,439],"proliferation":[23,243,346],"progression":[25],"in":[26,57,148,157,168,253,271,282,344],"many":[27,75],"human":[28],"epithelial":[29],"tumors.":[30,425],"Following":[31],"more":[32],"than":[33],"20":[34],"years":[35],"preclinical":[37],"development,":[38],"five":[39],"EGFR":[40,68,82,104,173,199,226,386],"inhibitors,":[41],"two":[42],"monoclonal":[43],"antibodies":[44],"three":[46],"small":[47],"molecule":[48],"inhibitors":[51,105],"(TKIs),":[52],"have":[53,70,268],"gained":[54],"FDA":[55],"approval":[56],"oncology":[58],"(panitumumab,":[59],"cetuximab,":[60],"erlotinib,":[61,224],"gefitinib":[62],"lapatinib).":[64],"Both":[65],"strategies":[66],"inhibition":[69,83],"demonstrated":[71,341],"clinical":[72,113],"successes.":[73],"However,":[74],"tumors":[76,288,297,308,340,364,396],"do":[77],"not":[78,213],"show":[79],"response":[80],"to":[81,92,103,123,140,155,163,175,194,218,223,234,330,363,380,399,419],"some":[85],"the":[87,93,135,149,172,337,389,412,415,435,440],"responders":[88],"eventually":[89],"manifest":[90],"resistance":[91,102,122,193,217,379,398],"treatment.":[94,368],"underlying":[96],"mechanisms":[97,119],"intrinsic":[99],"acquired":[101,121,192,216,378],"remain":[106],"an":[107,225],"intense":[108],"area":[109],"scientific":[111],"investigation.":[114],"To":[115,263],"explore":[116],"potential":[117],"molecular":[118],"cetuximab":[124,195,219,254,275,281,367,381,400,423],"we":[125,273],"established":[126],"series":[128,303],"cetuximab-resistant":[130],"clones":[131,143],"by":[132,186,203,245,259,349,358],"chronically":[133],"exposing":[134],"NCI-H226":[136],"NSCLC":[137],"cell":[138,242,345],"line":[139],"cetuximab.":[141,334],"Cetuximab-resistant":[142],"exhibited":[144,320],"dramatic":[146],"increase":[147,167],"steady-state":[150,169],"expression":[151,170],"EGFR,":[153],"due":[154],"alterations":[156],"trafficking":[158],"endocytosis":[160],"compared":[162,329,362],"parental":[164,277],"controls.":[165],"This":[166,206,406],"led":[174],"constitutive":[176],"activation":[177,239],"HER2":[179],"HER3":[181],"downstream":[183],"signals":[184],"mediated":[185],"MAPK":[187,238,390],"AKT.":[189],"Cells":[190],"with":[191,215,280,306,311,318,377,404,422],"remained":[196],"dependent":[197],"on":[198,210,333,366,385],"signaling":[200,387],"shown":[202],"RNAi":[204],"studies.":[205,285],"finding":[207],"prompted":[208],"investigation":[209],"whether":[211],"or":[212,324],"cells":[214,256,376],"would":[220],"be":[221,402],"sensitive":[222,276],"directed":[227],"TKI.":[228],"In":[229],"vitro,":[230],"erlotinib":[231,249,266,312,319,338,418],"was":[232],"able":[233],"decrease":[235,343],"AKT":[236,392],"subsequent":[241],"measured":[244,258,348,357],"BrdU":[246],"incorporation.":[247],"Additionally,":[248],"treatment":[250],"induced":[251],"apoptosis":[252],"resistant":[255,296,307,424],"Annexin":[260],"V":[261],"analysis.":[262],"determine":[264],"if":[265],"could":[267],"therapeutic":[269],"benefit":[270],"vivo,":[272],"treated":[274,290,310,317,339,403],"lines,":[278],"H226,":[279],"mouse":[283],"xenograft":[284],"Mice":[286,316],"harboring":[287],"were":[289,309],"for":[291,313,414,443],"approximately":[292],"70-150":[293],"days":[294],"before":[295],"manifested.":[298],"At":[299],"this":[300],"time":[301],"mice":[305],"15-30":[314],"days.":[315],"either":[321],"regression":[323],"tumor":[325],"delay":[327],"controls":[331],"maintained":[332,365],"Analysis":[335],"Ki67":[350],"higher":[352],"rates":[353],"apoptosis,":[355],"TUNEL":[359],"assays":[360],"when":[361],"work":[370,407],"presented":[371],"herein":[372],"suggest":[373],"that":[374],"1)":[375],"maintain":[382],"their":[383],"dependence":[384],"via":[388],"pathways":[393],"2)":[395],"developing":[397],"can":[401],"erlotinib.":[405],"may":[408],"provide":[409],"data":[410],"strengthening":[411],"rationale":[413],"use":[416],"treat":[420],"patients":[421],"Citation":[426],"Format:":[427],"{Authors}.":[428],"{Abstract":[429],"title}":[430],"[abstract].":[431],"In:":[432],"Proceedings":[433],"102nd":[436],"Annual":[437],"Meeting":[438],"American":[441],"Association":[442],"Cancer":[444,454],"Research;":[445],"2011":[446],"Apr":[447],"2-6;":[448],"Orlando,":[449],"FL.":[450],"Philadelphia":[451],"(PA):":[452],"AACR;":[453],"Res":[455],"2011;71(8":[456],"Suppl):Abstract":[457],"nr":[458],"726.":[459],"doi:10.1158/1538-7445.AM2011-726":[460]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2016-06-24T00:00:00"}